This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation, Editing/proofreading, Subtitling
Expertise
Specializes in:
Law: Patents, Trademarks, Copyright
Patents
Medical: Pharmaceuticals
Medical (general)
Food & Drink
Chemistry; Chem Sci/Eng
Botany
Biology (-tech,-chem,micro-)
Astronomy & Space
Tourism & Travel
Also works in:
Nutrition
Music
Manufacturing
History
Games / Video Games / Gaming / Casino
Cinema, Film, TV, Drama
Engineering (general)
Aerospace / Aviation / Space
More
Less
Portfolio
Sample translations submitted: 2
English to Indonesian: claim translation General field: Law/Patents Detailed field: Medical: Pharmaceuticals
Source text - English 8. The stable liquid pharmaceutical formulation of any one of claims 1-7, wherein the concentration of citrate is 5 mM to 50 mM.
9. A stable liquid pharmaceutical formulation comprising at least about 60 mg/ml to about 190mg/ml anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid, wherein the anti-α4β7 antibody comprises a light chain variable region comprising a complementarity determining region 1 (CDR1) comprising SEQ ID NO:11, a CDR2 comprising SEQ ID NO:12, a CDR3 comprising SEQ ID NO:13, and comprises a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:8, a CDR2 comprising SEQ ID NO:9, and a CDR3 comprising SEQ ID NO:10.
10. A stable liquid pharmaceutical formulation comprising an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid, wherein the anti-α4β7 antibody comprises a light chain variable region comprising a complementarity determining region 1 (CDR1) comprising SEQ ID NO:11, a CDR2 comprising SEQ ID NO:12, a CDR3 comprising SEQ ID NO:13, and comprises a heavy chain variable region comprising a CDR1 comprising SEQ ID NO:8, a CDR2 comprising SEQ ID NO:9, and a CDR3 comprising SEQ ID NO:10, and wherein the formulation has a pH of 6.1 to 7.0.
11. The stable liquid pharmaceutical formulation of claim 9 or 10, comprising about 150 mg/ml to about 180 mg/ml anti-α4β7 antibody.
12. The stable liquid pharmaceutical formulation of claim 9 or 10, wherein the antioxidant or chelator is citrate or EDTA.
13. The stable liquid pharmaceutical formulation of claim 12, wherein the antioxidant or chelator is citrate.
14. The stable liquid pharmaceutical formulation of claim 13, wherein the concentration of citrate is 5 mM to 50 mM.
15. The stable liquid pharmaceutical formulation of any one of claims 9-14, further comprising a surfactant.
16. The stable liquid pharmaceutical formulation of claim 15, wherein the surfactant:antibody molar ratio is from about 0.7:1 to about 2.0:1.
17. The stable liquid pharmaceutical formulation of claim 15, wherein the molar ratio of antioxidant or chelator to the surfactant is about 3:1 to about 156:1.
18. The stable liquid pharmaceutical formulation of claim 15, wherein the surfactant is polysorbate 20, polysorbate 80, a poloxamer and combinations thereof.
19. The stable pharmaceutical formulation of claim 18, wherein the surfactant is polysorbate 80 and the concentration of polysorbate 80 is 0.01% to 0.5%.
20. The stable liquid pharmaceutical formulation of claim 9 or 10, an anti-α4β7 antibody, citrate, histidine, arginine, and polysorbate 80.
Translation - Indonesian 8. Formulasi farmasi cair stabil dari salah satu klaim dari klaim 1 sampai 7, di mana konsentrasi sitrat adalah 5 mM sampai 50 mM.
9. Suatu formulasi farmasi cair stabil yang mengandung antibodi anti-α4β7sedikitnya sekitar 60 mg/ml sampai sekitar 190 mg/ml, suatu antioksidan atau pengkelat, dan sedikitnya satu asam amino bebas, di mana antibodi anti-α4β7 tersebut mencakup suatu daerah variabel rantai ringan yang mencakup suatu daerah penentu kompelementaritas 1 (CDR1) yang mencakup SEQ ID NO: 11, suatu CDR 2 yang mencakup SEQ ID NO: 12, suatu CDR3 yang mencakup SEQ ID NO: 13, dan mencakup suatu daerah variabel rantai berat yang mencakup suatu CDR1 yang mencakup SEQ ID NO: 8, suatu CDR2 yang mencakup SEQ ID NO: 9, dan suatu CDR3 yang mencakup SEQ ID NO:10.
10. Suatu formulasi farmasi cair yang mengandung suatu antibodi anti-α4β7, suatu antioksidan atau pengkelat, dan sedikitnya satu asam amino bebas, di mana antibodi anti-α4β7 tersebut mencakup suatu daerah variabel rantai ringan yang mencakup suatu daerah penentu kompelementaritas 1 (CDR1) yang mencakup SEQ ID NO: 11, suatu CDR 2 yang mencakup SEQ ID NO: 12, suatu CDR3 yang mencakup SEQ ID NO: 13, dan mencakup suatu daerah variabel rantai berat yang mencakup suatu CDR1 yang mencakup SEQ ID NO: 8, suatu CDR2 yang mencakup SEQ ID NO: 9, dan suatu CDR3 yang mencakup SEQ ID NO:10, dan di mana formulasi tersebut memiliki pH 6,1 sampai 7,0.
11. Formulasi farmasi cair stabil dari klaim 9 atau 10, yang mengandung antibodi anti-α4β7 sekitar 150 mg/ml sampai sekitar 180 mg/ml.
12. Formulasi farmasi cair stabil dari klaim 9 atau 10, di mana antioksidan atau pengkelat tersebut adalah sitrat atau EDTA.
13. Formulasi farmasi cair stabil dari klaim 12, di mana antioksidan atau pengkelat tersebut adalah sitrat.
14. Formulasi farmasi cair stabil dari klaim 13, di mana konsentrasi sitrat tersebut adalah 5 mM sampai 50 mM.
15. Formulasi farmasi cair stabil dari salah satu klaim dari klaim 9 sampai 14, yang selanjutnya mengandung suatu surfaktan.
16. Formulasi farmasi cair stabil dari klaim 15, di mana perbandingan molar surfaktan:antibodi tersebut adalah dari sekitar 0,7:1 sampai sekitar 2,0:1.
17. Formulasi farmasi cair stabil dari klaim 15, di mana perbandingan molar dari antioksidan atau pengkelat terhadap surfaktan adalah sekitar 3:1 sampai sekitar 156:1.
18. Formulasi farmasi cair stabil dari klaim 15, di mana surfaktan tersebut adalah polisorbat 20, polisorbat 80, suatu poloksamer dan kombinasinya.
19. Formulasi farmasi cair stabil dari klaim 18, di mana surfaktan tersebut adalah polisorbat 80 dan konsentrasi polisorbat tersebut adalah 0,01% sampai 0,5%.
20. Formulasi farmasi cair stabil dari klaim 9 atau 10 yang mengandung suatu antibodi anti-α4β7, sitrat, histidin, arginin, dan polisorbat 80.
English to Indonesian: ANTI-ASIC1 General field: Law/Patents Detailed field: Biology (-tech,-chem,micro-)
Source text - English ASIC are proton-gated cationic channels expressed in the central and peripheral nervous systems. The ASIC family in humans includes ASIC1, ASIC2, ASIC3 and ASIC4 subunits which arrange into homo- or heteromultimeric ion channels in neuronal membranes. ASIC1, ASIC2 and ASIC3 are significantly expressed in the small and medium nociceptive sensory neurons that are able to detect noxious chemical, thermal, and high threshold mechanical stimuli. ASIC2 and ASIC3 are also expressed in large neurons that mostly correspond to low threshold mechanoreceptors.
ASICs are permeable to Na+ and Ca2+ ions and are activated by external pH variations ranging from pH 6.8 to 4.0. ASICs are believed to play an important role in sensing local acidosis. Local tissue acidosis is a hallmark of pain and inflammation, and inflamed tissues frequently exhibit low pH (as low as ~4.7). Blockage of ASICs has been proposed as a method for treating a variety of disorders and conditions. Blockage of ASIC1 in particular has been proposed as a means for treating conditions such as pain, neurodegenerative diseases, and psychiatric diseases.
Pharmacologic inhibitors of ASIC1 include the tarantula peptide Psalmotoxin-1 (PcTx1) which specifically inhibits ASIC1 homomers, and the small molecule, non-selective ASIC inhibitors amiloride and A-317567. The 40 amino acid peptide toxin APETx2, isolated from sea anemone, has been shown to inhibit ASIC3 homomers as well as ASIC3/1 and ASIC3/2 heteromers.
Translation - Indonesian ASIC adalah kanal kationik yang bergerbang proton yang diekspresikan dalam sistem saraf pusat dan perifer. Famili ASIC pada manusia meliputi subunit ASIC1, ASIC2, ASIC3 dan ASIC4 yang tersusun menjadi kanal ion homomultimerik atau heteromultimerik pada membran neuronal. ASIC1, ASIC2 dan ASIC3 secara signifikan diekpresikan dalam neuron sensori nosiseptif kecil dan sedang yang mampu mendeteksi bahan kimia berbahaya, termal, dan stimulus mekanis ambang tinggi. ASIC2 dan ASIC3 juga diekspresikan dalam neuron yang besar yang sebagian besar bersesuaian dengan reseptor mekanis ambang rendah.
ASIC bersifat permeabel terhadap ion Na+ dan Ca2+ dan diaktifkan dengan variasi pH eksternal dengan kisaran pH dari pH 6,8 sampai 4,0. ASIC diyakini memainkan peran penting dalam penginderaan asidosis lokal. Asidosis jaringan lokal merupakan kekhasan dari nyeri dan inflamasi, dan jaringan yang mengalami inflamasi sering kali menunjukkan pH rendah (serendah ~4,7). Pemblokade ASIC telah diusulkan sebagai metode untuk mengobati berbagai gangguan dan kondisi. Pemblokadean ASIC1 khususnya telah diusulkan sebagai sarana untuk mengobati kondisi, seperti nyeri, penyakit-penyakit neurodegeneratif, dan penyakit-penyakit psikiatrik.
Inhibitor farmakologis ASIC1 meliputi peptida tarantula Psalmotoksin-1 (PcTx1) yang secara spesifik menghambat homomer ASIC1, dan inhibitor ASIC molekul kecil nonselektif amilorida, dan A-317567. Toksin peptida 40 asam amino APETx2, yang diisolasi dari anemon laut, telah ditunjukkan menghambat homomer ASIC3 serta heteromer ASIC3/1 dan ASIC3/2.
More
Less
Experience
Years of experience: 10. Registered at ProZ.com: Dec 2017.
Google Translator Toolkit, Microsoft Excel, Microsoft Office Pro, Microsoft Word, ProZ.com Translation Center, Trados Studio, Translation Workspace
Bio
I am Patent translation specialist, currently providing service in Patent and General translation from English to Bahasa Indonesia. I have been translating for 4 years plus with translated documents included, but not limited to pharmacy, biology, biotechnology, and other life science-related patent document. I will provide you with accurate and reliable services using my specialty in translating, drafting, editing and proofreading.
Keywords: patent, life science, pharmaceutical, medical, medicine, engineering, indonesia, bahasa indonesia, bahasa, biotechnology. See more.patent, life science, pharmaceutical, medical, medicine, engineering, indonesia, bahasa indonesia, bahasa, biotechnology, biology. See less.
Expertise